Sunday, September 20, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

View original at finance.yahoo.com
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna Roivant Sciences Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realiz…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Comirnaty sales represent approximately 2/3 of global COVID vaccine sales

    80% confidence
  • Outcome speaks to fundamental role that Genevant's foundational LNP technology played in enabling world's response to COVID-19 pandemic

    80% confidence
  • Moderna has finally acknowledged the seminal work of Arbutus scientists in enabling COVID-19 vaccines

    80% confidence
  • Settlement allows Genevant to put lengthy dispute behind them and remain focused on leveraging world-class nucleic acid delivery systems to bring innovative medicines to people

    80% confidence
  • It is gratifying for Genevant team to be recognized for pivotal contribution to restoring normalcy during COVID-19 pandemic

    80% confidence
  • Resolution with Moderna reduces uncertainty, validates Genevant IP estate and provides near term significant cash inflow

    80% confidence
  • Roivant will continue to be capital efficient with settlement proceeds, with additional $500 million authorized for share repurchases

    80% confidence
  • This is a transformative outcome for Arbutus and long-overdue recognition that COVID-19 vaccines would never have made it to the world without the seminal work of Arbutus scientists

    80% confidence
  • Arbutus scientists invented LNP delivery technology that changed the drug development landscape and enabled nucleic acids including mRNA to be used for medicines

    80% confidence
  • Section 1498 applies such that U.S. taxpayers should assume liability for Moderna's infringement of Genevant's and Arbutus' patents for sales made under government contracts

    80% confidence
  • If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com